Raphael Pharmaceutical (RAPH) Short term Debt (2020 - 2026)

Raphael Pharmaceutical has disclosed Short term Debt across 4 years of filings, most recently posting $43000.0 for Q2 2026.

• In Q2 2026, Short term Debt rose 4.88% year-over-year to $43000.0; the TTM figure through Jun 2026 stood at $43000.0 (up 4.88% YoY), while the FY2025 annual figure was $34000.0, down 17.07% from the prior year.
• Short term Debt came in at $43000.0 for Q2 2026 at Raphael Pharmaceutical, up from $34000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $43000.0 in Q2 2026 to a low of $34000.0 in Q4 2025.
• Average Short term Debt over 3 years is $40166.7, with a median of $41000.0 recorded in 2024.
• Year-over-year, Short term Debt declined 17.07% in 2025 and advanced 4.88% in 2026.
• Over 3 years, Short term Debt stood at $41000.0 in 2024, then retreated by 17.07% to $34000.0 in 2025, then grew by 26.47% to $43000.0 in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $43000.0 in Q2 2026, $34000.0 in Q4 2025, and $41000.0 in Q3 2025.